Product Images Clopidogrel
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Clopidogrel NDC 67046-100 by Contract Pharmacy Services-pa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
clopidogrel-75mg-30 - clopidogrel 75mg 30
Description: Clopidogrel is a medication used to prevent blood clots. It comes in the form of a tablet with a strength of 75 mg and is sold in packs of 30. The medication is prescription-only and is packaged by Contract Pharmacy Services-PA. The tablet should be stored between 15-30°C (59-86°F). The medication is to be taken as per package instructions. The pill contains clopidogrel bisulfate USP which is equivalent to 75 mg of clopidogrel base. The NDC number for this medication is 67046-100-30.*
Figure - clopidogrel fig1
This is a graph displaying the cumulative event rate in percentage for fatal or non-fatal vascular events for Aspirin and Clopidogrel Bisulfate over 36 months of follow-up. The graph shows that Aspirin has a higher cumulative event rate compared to Clopidogrel Bisulfate. There is also a statistical significance shown by the P-value of 0.045.*
Figure - clopidogrel fig2
Figure - clopidogrel fig3
Figure - clopidogrel fig4
This text provides data on a clinical trial for the medication Clopidogrel versus a placebo. It lists the number of deaths before the first discharge for each group and shows a 7% proportional risk reduction for those who took Clopidogrel. It includes a graph showing the number of days since randomization, up to 28 days.*
Figure - clopidogrel fig5
The text appears to be a statistical report on the effectiveness of Clopidogrel in reducing the risk of outcomes such as death, re-infarction, or stroke before first discharge compared to a placebo. The data shows that taking Clopidogrel resulted in a 9% proportional risk reduction (p = 0.002) compared to the placebo. The report also includes information on randomization up to 28 days.*
Figure - clopidogrel fig6
Change relative to clopidogrel bisulfate administered alone - clopidogrel fig8
Figure - clopidogrel fig9
This table shows the results of a study comparing the use of Clopidogrel and Aspirin in patients with qualifying conditions of stroke or PAD. The total number of patients included in the study was 19,185. The table presents the number and percentage of patients receiving each treatment option and the hazard ratio with a confidence interval. The results suggest that Clopidogrel is favored over Bisulfate and Aspirin, but more information is needed to fully interpret the findings.*
clopidogrel-str - clopidogrel str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.